cyrilzakka/clinical-trials huggingface dataset:
Noninvasive Internal Jugular Venous Oximetry

In this study, we are developing a novel plethysmographic monitoring device which incorporates several key techniques: inclusion of structural information (ultrasound image), coupling with the estimation of local tissue optical parameters, consideration of the tissue scattering absorption coefficient of each subject, to finally calculate the noninvasive continuous internal jugular venous saturation.

Central venous oxygen (ScvO2) is an important index for evaluating tissue perfusion in clinical care. To obtain the ScvO2 value, blood analysis must be obtained through a central venous catheter (CVC). Although CVC placement has a low incidence of complications, however, detrimental complications such as pneumothorax, hemothorax, infection and arrhythmia, are often fatal. In addition, continuous monitoring of ScvO2 often requires expensive equipment, so usually clinical caregivers can only take blood tests at specific care intervals, and may miss the opportunity to detect disease deterioration. In terms of anatomical structure and physiology, the values of internal jugular blood oxygen (SijvO2) and ScvO2 should be very close, and the evidence in the literature also points out that SijvO2 is not only highly similar to ScvO2, but also related to changes in cerebral blood oxygen. The internal jugular vein location is also an easier location for non-invasive continuous monitoring and thus it is interested to develop the novel technique for noninvasive continuous SijvO2 monitoring.

In this study, we are developing a novel plethysmographic monitoring device which incorporates several key techniques: inclusion of structural information (ultrasound image), coupling with the estimation of local tissue optical parameters, consideration of the tissue scattering absorption coefficient of each subject, to finally calculate the noninvasive continuous internal jugular venous saturation.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing major cancer surgery that requires central venous catheter placement
* Cancer patients undergoing totally implantable venous access device placement

Exclusion Criteria:

* Susepct infectious symptoms and signs (eg. white blood cell count count \>10000 ; fever \>38.3℃)
* impaired liver functions (aspartate aminotransferase\> 100 U/L); impaired renal function (estimated glomerular filtration rate \<60 mL/min/1.73 m2)
* heart failure, with New York Heart Associatation class 2 or more
Development and Validation of a Virtual Biopsy System in Kidney Transplant

Currently, kidney allograft biopsies are routinely performed to determine diagnosis and prognosis of kidney allografts. The histological interpretation of these biopsies is based on the Banff consensus for renal allograft pathology. The purpose of this study is to provide to the physicians a reliable estimation of renal allograft lesions of the day zero biopsy (kidney donor biopsy performed before transplantation).

In kidney transplantation, day-zero biopsies are essential to assess organ quality and discriminate the donor transmitted or acquired lesions and disease progression post-transplant. However, many centers worldwide do not perform those biopsies because they are invasive and costly. We aimed to develop and validate a non-invasive virtual biopsy system. Our goal was to provide clinicians with a virtual biopsy system to guide diagnostics, therapeutics and immediate patient management post-transplant and to minimize additional risks and costs to perform day-zero biopsies only using standard donor parameters. To circumvent these limitations, we sought to build and validate a virtual biopsy system that uses routinely collected donor parameters to predict kidney day-zero biopsy results. Since machine learning has demonstrated its clinical relevance in many medical specialties and superior performance to logistic regression, we based our analyses on machine learning methods as well as traditional statistical approaches using large and qualified international cohort donors who underwent routine and protocolized collection of donor parameters together with day-zero biopsy assessment using the standards of the international Banff allograft histopathology classification.

Eligibility Criteria:
Inclusion Criteria:

- Kidney donors who underwent kidney biopsies performed prior to kidney transplantation, aged at least 18 years old.

Exclusion Criteria:

* inadequate biopsies according to Banff international classification (number of glomeruli less than 10),
* biopsies with two or more Banff scores of interest missing.
PREOPERATIVE GONADOTROPINE-RELEASING HORMONE AGONIST THERAPY BEFORE SURGERY FOR UTERİN FIBROIDS

Uterin fibroids are the most common operation indication for hysterectomy. Dyring laparoscopic hysterectomy the amount of bleeding is a great difficulty.There are a lot of clinical researchs to reduce the haemorrhage during open hysterectomy but not laparoscopic procedure. In ALKU ERH clinic, researchers decided to smaller the size of fibroid by using GnRH analogues before total laparoscopic hysterectomy to reduce the haemorrhage amount.

After randomising patients to two groups, one of the group will be controle group and the other group will be working group and researchers decided to use 3,75 mg leuprolide acetate as GnRHa subcutanously in every four week, throughout 3 months before surgery to the working group, researchers will record intraoperative amount of bleeding by measuring the blood in suction scale, the duration of surgery, difference between preoperative haemoglobin levels and uterin weight. researchers will comparise all theese parameters ibn to two groups.

Eligibility Criteria:
Inclusion Criteria:

* MYOMA UTERI
* APPROPİATE FOR LAPAROSCOPY

Exclusion Criteria:

* MALİGNANCY
Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer

In this trial the investigators propose to utilize 13-cRA to prevent dysplastic changes and second malignancies in patients with squamous cell carcinoma of the head and neck regions who have a high probability of cure from their primary cancer. Comparisons between patients treated by 13-cRA and patients receiving placebo will include:

1. The time to diagnosis of second primary for the treatment versus control groups.
2. Survival time for the treatment versus control groups.
3. Secondarily, the cost-benefit ratio for 13-cRA will be analyzed by assessing the toxicities of 13-cis retinoic acid treated patients in comparison to those experienced by placebo treated patients.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent i obtained, the approved form is signed, and on file at the institution.
* Histologically confirmed squamous cell carcinoma.
* All chest x-rays and cervical spine x-rays done after definitive treatment within 35 days prior to randomization and all hematology andchemistries done within 2 weeks prior to randomization.
* The following sites and stages of cancers will be eligible. Oral Cavity

  1. T1 NO
  2. T2 NO 3.142 Oropharynx

  <!-- -->

  1. T1 NO
  2. T2 NO 3.143 Hypopharynx

  1. T1 NO 3.144 Larynx
  1. T1 NO
  2. T2 NO
* Age greater than 18 years.
* ECOG performance status 0 or 1.
* Patients must have adequate bone marrow, hepatic and renal function defined as follows: WBC \>3,500/mm, Platelets \> 125,000/mm.3 Total Bilirubin \< 2 mg%, Serum creatinine \< 2.5 mg%. Serum SGOT \< 2x normal, Alkaline Phosphatase \< 2x normal. Fasting Serum triglyceride levels \< 210 mg %. Fasting cholesterol \< 350 mg %. Patient may not be under systemic therapy for hyperlipidemia or have symptomatic arteriosclerotic coronary artery disease or have undergone coronary bypass surgery.
* The patient must have completed primary treatment of their cancer with surgery and/or radiation therapy within 730 days prior to randomization.
* The patient has had surgery and/or radiation therapy as outlined in Sections 5.0 and 6.0, and has been rendered disease-free.
* If currently receiving, patient must discontinue mega vitamin doses

Exclusion Criteria:

* Women of child bearing potential.
* Patient with severe coronary artery disease (Class III-IV New York Heart Association.)
* Histology other than squamous cell carcinoma.
* Distant metastases.
* Completion of previous treatment for their primary cancer with radiation, or surgery (except for biopsy) more than 730 days ago.
* Prior, synchronous, or concurrent malignancy except basal cell skin cancer.
* Failure to be rendered disease-free of primary tumor (includes positive surgical margins).
* The patient has had prior therapy other than that outlined in Sections 5.0 and 6.0 of the protocol.
Patient Transfer Monitoring System in Hospital Using Mobile IoT Technology

This trial is multi-center prospective study to develop Patient Transfer Monitoring system using mobile lot network and the Risk Factor Detection System and apply to real In-Hospital Patients and verify the efficacy.

Hospitalized patients who need transfer for a diagnostic examination or rehabilitation therapy during hospitalization, and have a risk of hypoxemia during transfer will be enrolled in this trial. The subjects will be provided with a portable oximeter and a smart-phone which application for monitoring is installed, and oxygen saturation and pulse rate will be checked in real time during transfer. The collected data will be transferred to cloud system via Iot network, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward. If there is a risk, the alarm system is activated so that the medical team is able to check risk factor and manage it immediately.

All the risk factors and severity will be collected during transfer, also these are checked whether the monitoring system and the data transmission system work properly or not, the time from detecting risk factor to medical response, the composition of medical staffs who responding to alarmed risk factors and improvement of the subjects.

Pilot study will be conducted with 20 subjects in Asan medical center. In pilot study, monitoring machines (HR, SpO2 monitor) commonly used in wards or hospitals will be used to verify the stability of oximeter used in this study and the developed risk detection system.

Eligibility Criteria:
Inclusion Criteria:

* A hospitalized patients in pulmonology department or rehabilitation hospital who have a risk of decreasing oxygen saturation
* A patients who require transfer in the hospital for a diagnostic examination or rehabilitation therapy during hospitalization
* Patients who need oxygen saturation monitoring according to the investigator's judgment
* Patients who voluntarily agree to study participation and provide written informed consent form

Exclusion Criteria:

* Patients who don't agree with the study procedure or are uncooperative
* Repeated monitoring of the same patient who already registered in the tiral
Biological Evaluation of Dietary Supplement Liposomal Glutathione

Low levels of antioxidant molecules such as glutathione have been found in people with a diagnosis of schizophrenia. However, oral glutathione is not well absorbed because the compound is mostly broken down in the gastrointestinal system. Liposomes are tiny droplets of oil particles that encapsulate and protect the glutathione. In this study we will evaluate a liposomal formulation of glutathione for tolerability and to examine if this formulation serves the function of increasing glutathione in the brain and body.

Additional information about this dietary supplement:

* Glutathione is an antioxidant naturally produced in our body. Glutathione protects the brain and other organs from oxidative stress.
* Low glutathione is associated with high oxidative stress, which has been linked to aging and many illnesses. Schizophrenia is a mental illness that doctors still do not fully understand. Individuals with schizophrenia often have low levels of glutathione.
* Glutathione can be supplied through dietary supplement. However, if taken plainly, it easily breaks down in our gut.
* Scientists have now found a way to wrap glutathione in tiny drops of oil particles called liposomes. That way, the gut cannot break it down so it is absorbed into our body. Once inside the body, our cells can take in the liposomes and use the glutathione to reduce oxidative stress.
* Liposome-wrapped glutathione is not a drug or medicine.

Eligibility Criteria:
Inclusion Criteria:

* Age range: 18-60
* DSM diagnosis of schizophrenia spectrum disorder, including schizophrenia, schizoaffective disorder, and schizophreniform disorder
* Ability to give written informed consent (Evaluation to Sign Consent score 10 or greater)
* Clinically stable with no change in antipsychotic medications nor significant increase of daily dose for 2 weeks prior to enrollment
* Low baseline blood glutathione level (GSH \< 890 umol/l)

Exclusion Criteria:

* History of major medical illness including, but not limited to, history of heart attack, stroke, TIA (transient ischemic attack)
* History of organic brain disorders that may affect neurophysiological measurements, including seizure disorder, brain tumor, head injury with evidence of significant cognitive deterioration
* DSM diagnosis of substance dependence within 6 months except nicotine and marijuana, or substance abuse in past month
* Uncontrolled blood pressure (persistent systolic above 165 or diastolic above 100)
* On medication containing cholesterol absorption inhibitor such as ezetimibe (Brand names Zetia, Ezetrol, Vytorin, and Inegy)
* Women who have positive urine pregnancy tests
* Women who plan to become pregnant, or are breastfeeding
* Unable to undergo MRI scanning due to metallic devices or objects or claustrophobia
* Already taking dietary antioxidant supplements such as n-acetylcysteine or fish oil on regular basis (more than twice a week) in the last 3 months
* History of allergy to soy or soy products
* Hyperlipidemia (baseline LDL \> 1.5 x upper limit of normal)
* Liver impairment (baseline AST or ALT \> 2.0 x upper limit of normal)
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia

The aim of this study is to test feasibility and efficacy of a dose reduced chemotherapy in elderly patients with newly diagnosed acute lymphoblastic leukemia. The regimen consists of induction phase I and II followed by cyclic consolidation cycles, reinduction and maintenance therapy


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of acute lymphoblastic leukemia (pro-B,common,pre-B,pre-T,Thy-,mature T, B-ALL)
* age \> 65 years
* written informed consent
* Karnofsky \> 50% (if not mainly caused by leukemia)
* laboratory at diagnosis or after supportive pre-treatment Creatinine \< 2 mg/dl Uric Acid \< 8 mg/dl Bilirubin \< 1.5 mg/dl ALA, ASA,AP \< 2.5 x ULN

Exclusion Criteria:

* severe second diseases (e.g. renal failure, cardiomyopathy etc., not caused by leukemia) that exclude treatment according to the protocol
* severe psychiatric illness or other circumstances which may compromise cooperation
* active second neoplasia
* clinical signs of life threatening infections or bleeding, uncontrollable prior to chemotherapy
Study of DC-CIK to Treat Colorectal Cancer

The purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).

60 patients with stage Ⅲ CRC, who had received neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, and got complete response (CR), will be randomly divided into group A (receive DC-CIK treatment) or group B (just regularly follow up), and the randomize ratio will be 1:1. Patients in group A will receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks). Patients in group B will have no anti-tumor therapy.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female patients ≥ 18 years of age;
2. CRC with histological diagnose, and had received neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy and got complete response (CR) with imaging;
3. Patients who have a life expectancy of at least 3 months;
4. Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1;
5. The bone marrow functioned normally (WBC \> 4.0×109/L, Hb \> 120 g/L, PLT \> 100×109/L);
6. The ECG results were normal, and the liver and kidney were functional.

Exclusion Criteria:

1. Patients who had distant metastases;
2. Patients with uncontrolled infection; underlying disease that was severe or life-threatening;
3. Patients who were pregnant or lactating;
4. ECOG perform status ≥ 2;
5. Patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment.
Urine Metabolomics and Colorectal Cancer Screening

This is a prospective, multi-centered study to assess whether urine metabolomics can play a role in the screening of colorectal cancer (CRC). Urine samples will be collected from 1000 patients going through an established CRC screening program, and from a further 500 patients who already have a diagnosis of CRC. Using nuclear magnetic resonance (NMR) spectroscopy, the 1H NMR spectrum of urine samples will be analyzed for specific metabolites, and establish the metabolomic signature of colorectal cancer. The results from metabolomic urinalysis of this screening cohort will be compared with results from colonoscopy, histological descriptions, fecal occult blood testing (FOBT), and fecal immune testing (FIT) to assess the accuracy of urine metabolomics in identifying patients with polyps and malignancies. The urine metabolomic results from the colorectal cancer group will be correlated with operative, histological and clinical staging to define the role of urine metabolomics in assessing colorectal cancer type, location and stage. Additionally approximately 300 urine samples from breast cancer patients and 300 from prostate cancer patients will be collected to validate that the colorectal cancer signature is unique.


Eligibility Criteria:
Inclusion Criteria:

For Screening group (normal colonoscopy \& colonic polyps):

* asymptomatic, 50-75 year old, without personal or family history of CRC/polyps
* asymptomatic, 40-75 year old, known personal or first-degree family history of either CRC or polyps

For Cancer group:

* any patient with diagnosis of colorectal cancer
* any patient with diagnosis of prostate cancer
* any patient with diagnosis of breast cancer

Exclusion Criteria:

For screening group:

* hematochezia
* inflammatory bowel disease
* on anticoagulation for reasons other than atrial fibrillation
* significant co-morbidities

For Cancer group:

* already had neoadjuvant treatment at time of urine collection
* no invasive cancer at time of urine collection
Aerobic Exercise to Improve Executive Language Function In Older Adults

The purpose of this study is to see if exercise can improve brain function in older adults

Recently, considerable attention has been devoted to examining the beneficial relationship between cognition and aerobic exercise in older adults. Specifically, the effects are thought to involve higher order cognitive processes, such as working memory, switching between tasks, and inhibiting irrelevant information, all of which are thought to be sub- served, in part, by the frontal lobes (Colcombe et al., 2006). Importantly, these areas also are most susceptible to age-related decline (Raz, 2000) and are essential resources for language production (Kemper \& Sumner, 2001; Murray \& Lenz, 2001). However, despite promising cognitive improvement, changes in frontally-mediated executive language functions have been widely ignored. This is unfortunate considering impaired word retrieval compromises communicative effectiveness, leading to frustration, depression, and withdrawal. Perhaps more importantly, communication ineffectiveness, particularly in the elderly, leads to difficulties interacting with health care professionals leading to further health care burdens. Since cognition, and specifically word retrieval difficulties, usually remain untreated, it is important to find treatment strategies for minimizing these deficits. Therefore, the short-term goal and the purpose of this proposal is to examine the potential of aerobic exercise to improve executive language function in older adults.

Eligibility Criteria:
Inclusion Criteria:

* Consent of participants' primary health care physicians to participate in the aerobic exercise.
* Patients must not have participated in any consistent exercise program or experimental study for at least 3 months prior to enrollment.
* They must be capable of providing informed consent and complying with the trial procedures.

Exclusion Criteria:

* Demented as defined by the Modified Mini Mental Status Exam.
* Unalterable travel schedules.
* Site accessibility constraints.
Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma

This cohort study compares immune response induced in two groups of small HCC patients treated by ablation (group1 RFA, group 2 MWA). Patients will benefit for tumoral and non tumoral biopsies prior to treatment and stepped peripheral blood samples juste before ablation and during the first month after.


Eligibility Criteria:
Inclusion Criteria:

* Histologically proven HCC for less than 3 months before ablation
* Decision of ablation treatment in multidisciplinary meeting

Exclusion Criteria:

* Fibrolamellar HCC
* Hepatocholangiocarcinoma
"Awareness, Preconception, and Fear of Epidural Analgesia Among Childbearing Women in Saudi Arabia."

The aim of our study is to measure the level of awareness, preconceptions, and level of fear regarding epidural analgesia among childbearing women in KKUH in Riyadh.

This research was designed as a hospital-based observational cross-sectional study conducted at King Khalid University Hospital, using a self-administered questionnaire based on previous research.22-24-26 approved by the Institutional Review Board at King Saud University, College of Medicine, Riyadh, Saudi Arabia on 08.August.2022 Ref. No. 22/0592/IRB. The sample included pregnant women attending an obstetrical clinic for routine antenatal follow-up, and the data collection was conducted during the month of August 2022. The questionnaire included five parts (sociodemographic, preconception, awareness, fear, and desirability). a total of 26 questions with multiple-choice answers. The sample size was determined using the Comrey and Lee criterion Comrey and Lee (1992) stated that a 200-sample size is acceptable. The questionnaire was completed by 202 participants who met the inclusion criteria that is being a pregnant woman and completing the survey, and the exclusion criteria were non-pregnant women and an incomplete survey. The data collectors made it clear to the participants that taking part in the study was completely optional, and the participants signed anonymous consent forms.

Eligibility Criteria:
Inclusion Criteria:

* pregnant woman
* completing the survey

Exclusion Criteria:

* non-pregnant women
* incomplete survey